{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:28:35Z","timestamp":1793744915875,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["02NUK084A"],"award-info":[{"award-number":["02NUK084A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Projektnummer 318,346,496-SFB1292\/2TP19N"],"award-info":[{"award-number":["Projektnummer 318,346,496-SFB1292\/2TP19N"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ctro.2026.101315","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:22:20Z","timestamp":1791501740000},"page":"101315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Delayed elective nodal irradiation in head-and-neck cancer radiotherapy reduces acute lymphocyte damage, lymphopenia, and modulates immune signatures"],"prefix":"10.1016","volume":"62","author":[{"given":"Justus","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Drabke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Gercek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Breinich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Oebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Schmidberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Zahnreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101315_bb0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/jso.23724","article-title":"Current treatment of head and neck squamous cell cancer","volume":"110","author":"Belcher","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0010","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2026.101315_bb0015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2026.101315_bb0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0025","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101315_bb0030","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1634\/theoncologist.2017-0674","article-title":"CheckMate 141: 1-year update and subgroup analysis of Nivolumab as first-line therapy in patients with recurrent\/metastatic head and neck cancer","volume":"23","author":"Gillison","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ctro.2026.101315_bb0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant Pembrolizumab in locally advanced head and neck Cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101315_bb0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(25)01850-1","article-title":"Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial","volume":"407","author":"Bourhis","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2026.101315_bb0050","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"issue":"20","key":"10.1016\/j.ctro.2026.101315_bb0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0060","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctro.2026.101315_bb0065","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctro.2026.101315_bb0070","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctro.2026.101315_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000867","article-title":"Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy","volume":"8","author":"Buchwald","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctro.2026.101315_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31941-w","article-title":"Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC","volume":"13","author":"Saddawi-Konefka","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctro.2026.101315_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ctro.2026.101315_bb0090","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and Meta-analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101315_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.103873","article-title":"Relationship between elective neck irradiation and severe lymphopenia in patients treated with head and neck Chemoradiotherapy","volume":"44","author":"Mickel","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctro.2026.101315_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110041","article-title":"Modeling frameworks for radiation induced lymphopenia: a critical review","volume":"190","author":"Cella","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0105","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1667\/RR13911.1","article-title":"Biodosimetry based on gamma-H2AX quantification and cytogenetics after partial- and Total-body irradiation during fractionated radiotherapy","volume":"183","author":"Zahnreich","year":"2015","journal-title":"Radiat Res"},{"key":"10.1016\/j.ctro.2026.101315_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2019.01.018","article-title":"Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 update","volume":"134","author":"Biau","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.oraloncology.2018.08.011","article-title":"Target delineation for postoperative treatment of head and neck cancer","volume":"86","author":"Evans","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.103294","article-title":"A generalised method for calculating repopulation-corrected tumour EQD2 values in a wide range of clinical situations, including interrupted treatments","volume":"118","author":"Dale","year":"2024","journal-title":"Phys Med"},{"key":"10.1016\/j.ctro.2026.101315_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cells14100682","article-title":"Effects of cisplatin on the radiation response and DNA damage markers in peripheral blood lymphocytes ex vivo","volume":"14","author":"Zahnreich","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ctro.2026.101315_bb0130","series-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","author":"Anon","year":"2017"},{"key":"10.1016\/j.ctro.2026.101315_bb0135","series-title":"Decoding Radiation-Induced Transcriptomic Signatures of Whole Blood Using Long-Read RNA-Seq: Clinical and Biodosimetric Implications","author":"Salah","year":"2026"},{"key":"10.1016\/j.ctro.2026.101315_bb0140","doi-asserted-by":"crossref","first-page":"19840","DOI":"10.1038\/s41598-025-04898-1","article-title":"Genome-wide transcriptomic response of whole blood to radiation","volume":"15","author":"Salah","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctro.2026.101315_bb0145","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ctro.2026.101315_bb0150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.ctro.2026.101315_bb0155","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.22.00980","article-title":"Results of phase III randomized trial for use of docetaxel as a Radiosensitizer in patients with head and neck Cancer, unsuitable for cisplatin-based Chemoradiation","volume":"41","author":"Patil","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0160","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1667\/RR14475.1","article-title":"Quantification of radiation biomarkers in leukocytes of breast cancer patients treated with different modalities of 3D-CRT or IMRT","volume":"186","author":"Zahnreich","year":"2016","journal-title":"Radiat Res"},{"key":"10.1016\/j.ctro.2026.101315_bb0165","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/s41598-021-81058-1","article-title":"Comparison of DNA repair and radiosensitivity of different blood cell populations","volume":"11","author":"Heylmann","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctro.2026.101315_bb0170","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1269\/jrr.45.195","article-title":"Chromosomal aberrations in lymphocytes of lung cancer patients treated with carbon ions","volume":"45","author":"Lee","year":"2004","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ctro.2026.101315_bb0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nature02238","article-title":"T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases","volume":"427","author":"Mempel","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ctro.2026.101315_bb0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13014-025-02641-8","article-title":"Combined spatial and Dosimetric recurrence pattern analysis in head and neck squamous cell carcinoma following postoperative (chemo)radiotherapy","volume":"20","author":"Schr\u00f6ter","year":"2025","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0185","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00405-022-07800-1","article-title":"Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients","volume":"280","author":"C\u00e9saire","year":"2023","journal-title":"Eur Arch Otorrinolaringol"},{"key":"10.1016\/j.ctro.2026.101315_bb0190","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2020.01.032","article-title":"Absolute lymphocyte count predicts Abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1\/2 trials","volume":"108","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101315_bb0195","doi-asserted-by":"crossref","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctro.2026.101315_bb0200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40425-018-0395-x","article-title":"Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas","volume":"6","author":"Ho","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctro.2026.101315_bb0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3892\/mco.2020.2157","article-title":"Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma","volume":"13","author":"Park","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101315_bb0210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2017.07.033","article-title":"Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1\/PD-L1 inhibitors)","volume":"84","author":"Sun","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctro.2026.101315_bb0215","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00262-024-03810-6","article-title":"A comprehensive and longitudinal evaluation of the different populations of lymphoid and myeloid cells in the peripheral blood of patients treated with chemoradiotherapy for head and neck cancer","volume":"73","author":"Von Der Gr\u00fcn","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctro.2026.101315_bb0220","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.18295\/2075-0528.1648","article-title":"The role of damage-associated molecular patterns in human diseases: part I - promoting inflammation and immunity","volume":"15","author":"Land","year":"2015","journal-title":"Sultan Qaboos Univ Med J"},{"key":"10.1016\/j.ctro.2026.101315_bb0225","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41423-024-01148-8","article-title":"Cellular metabolism regulates the differentiation and function of T-cell subsets","volume":"21","author":"Ma","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ctro.2026.101315_bb0230","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nri3660","article-title":"Emergency granulopoiesis","volume":"14","author":"Manz","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctro.2026.101315_bb0235","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ctro.2026.101315_bb0240","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.adx4381","article-title":"Sex differences in tissue-specific immunity and immunology","volume":"389","author":"Sharma","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ctro.2026.101315_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104843","article-title":"Gender differences in radiotherapy: a critical review","volume":"215","author":"D'Ippolito","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctro.2026.101315_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1699362","article-title":"Sex-specific differences in abscopal responses to combined radiotherapy and immune checkpoint inhibition\u2013insights from a multicenter study","volume":"16","author":"Trommer","year":"2026","journal-title":"Front Immunol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826002107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826002107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:03:41Z","timestamp":1793743421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826002107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":50,"alternative-id":["S2405630826002107"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101315","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed elective nodal irradiation in head-and-neck cancer radiotherapy reduces acute lymphocyte damage, lymphopenia, and modulates immune signatures","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101315"}}